Patents by Inventor Mien-Chie Hung

Mien-Chie Hung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220389106
    Abstract: Provided herein are agents, such as antibodies, antibody-drug conjugates, or chimeric antigen receptors, that target EphA10. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an EphA10-targeting agent. The patient may be selected for treatment if the cancer expresses an increased level of EphA10.
    Type: Application
    Filed: September 18, 2020
    Publication date: December 8, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Mien-Chie HUNG, Jong-Ho CHA, Li-Chuan CHAN
  • Publication number: 20220364181
    Abstract: A method for predicting susceptibility to stimulator of interferon genes (STING) agonists of a cancer patient is provided, comprising (1) obtaining at least one sample from the cancer patient; (2) detecting an expression level of S-methyl-5?-thioadenosine phosphorylase (MTAP) in the at least one sample by using at least one specific probe; and (3) if MTAP is expressed in the at least one sample, then predicting that the cancer patient has high-susceptibility to STING agonists and providing STING agonists to treat the cancer patient; otherwise providing non-STING agonists for treatment.
    Type: Application
    Filed: May 14, 2022
    Publication date: November 17, 2022
    Applicant: China Medical University
    Inventors: Mien-Chie Hung, Jung-Mao Hsu
  • Publication number: 20220305015
    Abstract: Provided herein are methods for identifying and treating cancers that are resistant to PARP inhibition. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided. In some aspects, PARP inhibitor cancers are treated with a PARP inhibitor therapy in combination with a receptor tyrosine kinase inhibitor.
    Type: Application
    Filed: June 10, 2020
    Publication date: September 29, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Mien-Chie HUNG, Mei-Kuang CHEN, Yu-Yi CHU
  • Patent number: 11452775
    Abstract: This invention provides biomarkers (e.g., methylation of R198 or R200 of EGFR or the presence of an arginine at position 497 of EGFR) for the prediction of resistance to cetuximab therapy. This invention also provides methods for the selection of patients for combination therapy with cetuximab and PRMT inhibitors.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: September 27, 2022
    Assignee: Board of Regents, The University of Texas System
    Inventors: Mien-Chie Hung, Hsin-Wei Liao, Jung-Mao Hsu
  • Publication number: 20220276252
    Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.
    Type: Application
    Filed: November 13, 2020
    Publication date: September 1, 2022
    Applicants: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
    Inventors: Stephen S. YOO, Ezra M. CHUNG, Yong-Soo KIM, Mien-Chie HUNG, Chia-Wei LI, Seung-Oe LIM
  • Publication number: 20220155307
    Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.
    Type: Application
    Filed: November 13, 2020
    Publication date: May 19, 2022
    Applicants: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS
    Inventors: Stephen S. YOO, Ezra M. CHUNG, Yong-Soo KIM, Mien-Chie HUNG, Chia-Wei LI, Seung-Oe LIM
  • Publication number: 20210386695
    Abstract: The present disclosure relates to a method for inhibiting a binding of a SARS-CoV-2 spike protein of a SARS-CoV-2 to an angiotensin-converting enzyme 2 including contacting the SARS-CoV-2 with a sufficient concentration of disulfiram, a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of disulfiram, and a method for inhibiting an activity of a papain-like protease (PLpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of disulfiram. A method for inhibiting a replication or an infection of a SARS-CoV-2 in a cell includes contacting the cell with a sufficient concentration of disulfiram and a medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of disulfiram are also provided.
    Type: Application
    Filed: June 16, 2021
    Publication date: December 16, 2021
    Applicant: China Medical University
    Inventors: Chang-Hai Tsai, Mien-chie Hung, Yeh Chen, Wen-Hao Yang, Chia-shin Yang, Yu-Lin Hung, Yu-Chuan Wang, Yi-Zhen Chou, Mei-Hui Hou, Chia-Ling Tsai, Bao-Yue Huang, Chian-Fang Hung, Hsiao-Fan Chen, Wen-Chi Su, Wei-Jan Wang
  • Publication number: 20210330661
    Abstract: The present disclosure relates to a method for preventing or inhibiting a synthesis of viral RNA of SARS-CoV-2 in a cell including contacting the cell with a sufficient concentration of tafenoquine, boceprevir or narlaprevir and a method for inhibiting an activity of a main protease (Mpro) of SARS-CoV-2 including contacting a SARS-CoV-2 with a sufficient concentration of tafenoquine, boceprevir or narlaprevir. A medical composition for use in a treatment of an infection of SARS-CoV-2 including a therapeutically effective amount of tafenoquine, boceprevir or narlaprevir is also provided.
    Type: Application
    Filed: April 22, 2021
    Publication date: October 28, 2021
    Applicant: China Medical University
    Inventors: Mien-Chie Hung, Yeh Chen, Wen-Hao Yang, Chia-Shin Yang, Yu-Lin Hung, Yu-Quan Wang, Yi-Zhen Chou, Mei-Hui Hou, Chia-Ling Tsai, Bao-Yue Huang, Chian-Fang Hung
  • Publication number: 20210156866
    Abstract: Provided herein are methods of detecting glycosylated proteins, such as immune checkpoint proteins. Further provided are methods of treating cancer, such as by administering immune checkpoint inhibitors.
    Type: Application
    Filed: June 7, 2019
    Publication date: May 27, 2021
    Applicant: Board of Regents, The University of Texas System
    Inventors: Heng-Huan LEE, Ying-Nai WANG, Mien-Chie HUNG
  • Publication number: 20210139588
    Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.
    Type: Application
    Filed: November 13, 2020
    Publication date: May 13, 2021
    Applicants: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Stephen S. YOO, Ezra M. CHUNG, Yong-Soo KIM, Seung-Oe LIM, Chia-Wei LI, Mien-Chie HUNG
  • Patent number: 10858432
    Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 8, 2020
    Assignees: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Stephen S. Yoo, Ezra M. Chung, Yong-Soo Kim, Seung-Oe Lim, Chia-Wei Li, Mien-Chie Hung
  • Patent number: 10836827
    Abstract: Antibodies that bind specifically to glycosylated PD-L1 relative to unglycosylated PD-L1 are provided. Antibodies that recognize specific epitopes of glycosylated PD-L1 protein and can block the binding of PD-L1 to PD-1 are provided. In some aspects, PD-L1 polypeptides comprising glycosylated amino acid residues at amino and carboxy terminal positions of the PD-L1 extracellular domain are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: November 17, 2020
    Assignees: STCUBE, INC., BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Stephen S. Yoo, Ezra M. Chung, Yong-Soo Kim, Mien-Chie Hung, Chia-Wei Li, Seung-Oe Lim
  • Publication number: 20200093926
    Abstract: This invention provides biomarkers (e.g., methylation of R198 or R200 of EGFR or the presence of an arginine at position 497 of EGFR) for the prediction of resistance to cetuximab therapy. This invention also provides methods for the selection of patients for combination therapy with cetuximab and PRMT inhibitors.
    Type: Application
    Filed: December 4, 2019
    Publication date: March 26, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: Mien-Chie HUNG, Hsin-Wei LIAO, Jung-Mao HSU
  • Patent number: 10537635
    Abstract: This invention provides biomarkers (e.g., methylation of R198 or R200 of EGFR or the presence of an arginine at position 497 of EGFR) for the prediction of resistance to cetuximab therapy. This invention also provides methods for the selection of patients for combination therapy with cetuximab and PRMT inhibitors.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: January 21, 2020
    Assignee: Board of Regents, The University of Texas System
    Inventors: Mien-Chie Hung, Hsin-Wei Liao, Jung-Mao Hsu
  • Publication number: 20190369106
    Abstract: Provided herein are methods and compositions for the detection and standard free quantitation of antigens of interest. Further provided are methods for the absolute quantitation of proteins in solution, cells, or tissues. Also provided are methods for determining the on-target binding constant of a therapeutic agent to its target in a biological sample.
    Type: Application
    Filed: May 29, 2019
    Publication date: December 5, 2019
    Inventors: Mien-Chie HUNG, Chao-Kai CHOU, Pei-Hsiang TSOU, Po-Jung HUANG, Jun KAMEOKA
  • Patent number: 10451610
    Abstract: Provided herein are methods for identifying and treating cancers that are resistant to PARP inhibition. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided. In some aspects. PARP inhibitor cancers are treated with a PARP inhibitor therapy in combination with a c-Met inhibitor therapy.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: October 22, 2019
    Assignee: Board of Regents, The University of Texas System
    Inventors: Mien-Chie Hung, Yi Du
  • Publication number: 20190218297
    Abstract: Anti-cancer treatment and therapeutic methods are provided in which an antibody that binds specifically to glycosylated PD-L1 relative to unglycosylated PD-L1 and blocks binding of PD-L1 to PD-1 is administered to a subject in need in combination with an antibody that binds specifically to glycosylated PD-L1 relative to unglycosylated PD-L1, blocks binding of PD-L1 to PD-1 and also promotes internalization and degradation of PD-L1. The anti-cancer methods utilize antibodies that recognize specific epitopes on glycosylated PD-L1 protein, as well as antibodies that exhibit the IPD function of both blocking the binding of PD-L1 to PD-1 and also facilitating the internalization of PD-L1 on cells expressing PD-L1. Methods in which such antibody combinations are especially useful include cancer and tumor treatments and therapies in which the cancer or tumor is a PD-L1 positive cancer or tumor.
    Type: Application
    Filed: July 19, 2017
    Publication date: July 18, 2019
    Inventors: Stephen S. YOO, Mien-Chie HUNG, Chia-Wei LI, Seung-Oe LIM
  • Publication number: 20190105403
    Abstract: Methods for producing and screening for antibodies that specifically bind to glycosylated immune checkpoint proteins (ICPs) relative to non-glycosylated ICPs are provided. Such antibodies recognize specific epitopes of glycosylated ICPs and can prevent or block the binding of a glycosylated ICP with its ligand, such as another ICP, and can inhibit the interactions between the two proteins that can lead to immunosuppression, as exemplified by the human PD-L1/PD-1 interaction. By way of specific example, human PD-L1 and PD-1 polypeptides comprising glycosylated amino acid residues within their extracellular domains are provided for generating anti-glycosylated PD-L1 or anti-glycosylated PD-1 antibodies that specifically bind PD-L1 or PD-1, respectively, and inhibit the PD-L1/PD-1 interaction. The antibodies produced and selected by the methods are especially useful as cancer therapeutics for disrupting, blocking, or neutralizing the ICP system and specific ICP interactions therein.
    Type: Application
    Filed: March 24, 2017
    Publication date: April 11, 2019
    Inventors: Stephen S. YOO, Mien-Chie HUNG
  • Publication number: 20190083644
    Abstract: Antibodies that bind specifically to glycosylated PD-L1 relative to unglycosylated PD-L1, block binding of PD-L1 to PD-1 and promote internalization and degradation of PD-L1 are provided. Antibodies that recognize specific epitopes on glycosylated PD-L1 protein and that exhibit the dual functions of both blocking the binding of PD-L1 to PD-1 and also facilitating the internalization of PD-L1 on cells are provided. In some aspects, PD-L1 polypeptides comprising glycosylated amino acid residues at amino and carboxy terminal positions of the PD-L1 extracellular domain are also provided. Methods for using such antibodies for the treatment of cancer, particularly PD-L1 positive cancer, are also provided.
    Type: Application
    Filed: March 24, 2017
    Publication date: March 21, 2019
    Inventors: Stephen S. YOO, Ezra M. CHUNG, Yong-Soo KIM, Kyu Lee HAN, Andrew H. PARK, Mien-Chie HUNG, Chia-Wei LI, Seung-Oe LIM
  • Publication number: 20190077866
    Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.
    Type: Application
    Filed: December 1, 2016
    Publication date: March 14, 2019
    Inventors: Stephen S. YOO, Ezra M. CHUNG, Yong-Soo KIM, Seung-Oe LIM, Chia-Wei LI, Mien-Chie HUNG